Drug releasing coatings for medical devices
The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups.
1. A method for treating a blood vessel, the method comprising:
inserting a balloon catheter to a target site in the blood vessel, the balloon catheter comprising a balloon and a coating layer overlying external surfaces of the balloon, wherein:
the coating layer comprises a water-soluble first additive, a water-soluble second additive, and an initial drug load of a hydrophobic therapeutic agent;
the coating layer does not include an iodine covalent-bonded contrast agent, a dye, an oil, or a lipid;
the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, paclitaxel analogues, rapamycin, rapamycin analogues, and combinations thereof;
the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;
the water-soluble first additive is a surfactant selected from the group consisting of PEG sorbitan monolaurates, PEG sorbitan monooleates, and combinations thereof;
the water-soluble second additive is a chemical compound having at least four hydroxyl groups, the chemical compound being selected from the group consisting of sorbitol, sorbitan, xylitol, gluconolactone, and combinations thereof,
whereby the combination of the water-soluble first additive and the water-soluble second additive promotes rapid release of the hydrophobic therapeutic agent from the balloon at the target site during an inflation period;
inflating the balloon until the coating layer contacts walls of the blood vessel at the target site;
deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 10 minutes; and
withdrawing the balloon catheter from the blood vessel, the balloon having thereon a residual drug amount after the withdrawing.
2. The method of claim 1 , wherein the ratio by weight of the therapeutic agent in the coating layer to the total weight of the first and second additives in the coating layer is from about 0.5 to 3.
3. The method of claim 1 , wherein the initial drug load is from 1 μg to 20 μg of the hydrophobic therapeutic agent per square millimeter of the balloon.
4. The method of claim 1 , wherein:
the initial drug load is from 2 μg to 6 μg of the hydrophobic therapeutic agent per square millimeter of the balloon; and
the residual drug amount is 24.7% or less of the initial drug load.
5. The method of claim 1 , wherein:
the water-soluble first additive is selected from the group consisting of PEG (20) sorbitan monolaurate, PEG (20) sorbitan monooleate, and combinations thereof.
6. The method of claim 1 , wherein:
the water-soluble first additive is selected from the group consisting of PEG (20) sorbitan monolaurate, PEG (20) sorbitan monooleate, and combinations thereof; and
the water-soluble second additive is selected from the group consisting of sorbitol, gluconolactone, and combinations thereof.
7. The method of claim 1 , wherein:
the water-soluble first additive is PEG (20) sorbitan monolaurate or PEG (20) sorbitan monooleate; and
the water-soluble second additive is selected from the group consisting of sorbitol, xylitol, gluconolactone, and combinations thereof.
8. The method of claim 1 , wherein:
the coating layer consists essentially of the therapeutic agent, the first additive, and the second additive;
the water-soluble first additive is PEG (20) sorbitan monolaurate or PEG (20) sorbitan monooleate; and
the water-soluble second additive is sorbitol.
9. The method of claim 1 , wherein:
the coating layer consists essentially of the therapeutic agent, the first additive, and the second additive;
the water-soluble first additive is PEG (20) sorbitan monolaurate or PEG (20) sorbitan monooleate; and
the water-soluble second additive is gluconolactone.
10. The method of claim 1 , wherein:
the hydrophobic therapeutic agent is paclitaxel;
the water-soluble first additive is PEG (20) sorbitan monolaurate;
the water-soluble second additive is sorbitol;
the initial drug load is from 2 μg to 6 μg of the hydrophobic therapeutic agent per square millimeter of the balloon; and
the residual drug amount is 24.7% or less of the initial drug load.
11. The method of claim 10 , wherein the ratio by weight of the hydrophobic therapeutic agent in the coating layer to the total weight of the water-soluble first and second additives in the coating layer is from about 0.1 to 5.
12. The method of claim 10 , wherein:
the coating layer consists essentially of paclitaxel, PEG (20) sorbitan monolaurate, and sorbitol; and
the ratio by weight of paclitaxel in the coating layer to the total weight of PEG (20) sorbitan monolaurate and sorbitol in the coating layer is from about 0.5 to 3.
13. The method of claim 10 , wherein:
the coating layer consists essentially of paclitaxel, PEG (20) sorbitan monooleate, and sorbitol; and
the ratio by weight of paclitaxel in the coating layer to the total weight of PEG (20) sorbitan monooleate and sorbitol in the coating layer is from about 0.5 to 3.
14. A method for treating a blood vessel, the method comprising:
inserting a balloon catheter to a target site in the blood vessel, the balloon catheter comprising a balloon and a coating layer overlying external surfaces of the balloon, wherein:
the coating layer comprises a water-soluble first additive, a water-soluble second additive, and a hydrophobic therapeutic agent with an initial drug load of from 2 μg to 6 μg of the hydrophobic therapeutic agent per square millimeter of the balloon;
the coating layer does not include an iodine covalent-bonded contrast agent, a dye, an oil, or a lipid;
the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, paclitaxel analogues, rapamycin, rapamycin analogues, and combinations thereof;
the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;
the water-soluble first additive is a surfactant selected from the group consisting of PEG (20) sorbitan monolaurate and PEG (20) sorbitan monooleate, and combinations thereof;
the water-soluble second additive is a chemical compound having at least four hydroxyl groups, the chemical compound being selected from the group consisting of sorbitol, xylitol, gluconolactone, lactobionic acid, and combinations thereof; and
the ratio by weight of the hydrophobic therapeutic agent in the coating layer to the total weight of the water-soluble first and second additives in the coating layer is from about 0.1 to 5,
whereby the combination of the water-soluble first additive and the water-soluble second additive promotes rapid release of the hydrophobic therapeutic agent from the balloon at the target site during an inflation period;
inflating the balloon until the coating layer contacts walls of the blood vessel at the target site;
deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 10 minutes; and
withdrawing the balloon catheter from the blood vessel, the balloon having thereon a residual drug amount of less than 24.7% of the initial drug load after the withdrawing.
15. The method of claim 14 , wherein:
the water-soluble first additive is PEG (20) sorbitan monolaurate; and
the water-soluble second additive is gluconolactone.
16. The method of claim 14 , wherein:
the water-soluble first additive is PEG (20) sorbitan monolaurate; and
the water-soluble second additive is sorbitol or xylitol.
17. The method of claim 14 , wherein:
the water-soluble first additive is PEG (20) sorbitan monolaurate; and
the water-soluble second additive is lactobionic acid.
18. The method of claim 14 , wherein:
the water-soluble first additive is PEG (20) sorbitan monooleate; and
the water-soluble second additive is gluconolactone.
19. The method of claim 14 , wherein:
the water-soluble first additive is PEG (20) sorbitan monooleate; and
the water-soluble second additive is sorbitol or xylitol.
20. A method for treating a blood vessel, the method comprising:
inserting a balloon catheter to a target site in the blood vessel, the balloon catheter comprising a balloon and a coating layer overlying external surfaces of the balloon, wherein:
the coating layer comprises a water-soluble first additive, a water-soluble second additive, and an initial drug load of a hydrophobic therapeutic agent;
the coating layer does not include an iodine covalent-bonded contrast agent, a dye, an oil, or a lipid;
the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, paclitaxel analogues, rapamycin, rapamycin analogues, and combinations thereof;
the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;
the water-soluble first additive is a surfactant selected from the group consisting of PEG (20) sorbitan monolaurate, PEG (20) sorbitan monooleate, and combinations thereof;
the water-soluble second additive is a chemical compound having at least four hydroxyl groups, the chemical compound being selected from the group consisting of sorbitol, xylitol, gluconolactone, lactobionic acid, and combinations thereof,
whereby the combination of the water-soluble first additive and the water-soluble second additive promotes rapid release of the hydrophobic therapeutic agent from the balloon at the target site during an inflation period;
inflating the balloon until the coating layer contacts walls of the blood vessel at the target site;
deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 2 minutes; and
withdrawing the balloon catheter from the blood vessel, the balloon having thereon a residual drug amount after the withdrawing.
21. The method of claim 20 , wherein:
the initial drug load is from 2 μg to 6 μg of the hydrophobic therapeutic agent per square millimeter of the balloon; and
the residual drug amount is 24.7% or less of the initial drug load.
22. The method of claim 21 , wherein the water-soluble first additive is PEG (20) sorbitan monolaurate.
23. The method of claim 21 , wherein the water-soluble second additive is sorbitol or gluconolactone.
24. The method of claim 21 , wherein:
the coating layer consists essentially of paclitaxel, PEG (20) sorbitan monolaurate, and sorbitol; and
the ratio by weight of paclitaxel in the coating layer to the total weight of PEG (20) sorbitan monolaurate and sorbitol in the coating layer is from about 0.1 to 5.
25. The method of claim 21 , wherein:
the coating layer consists essentially of paclitaxel, PEG (20) sorbitan monooleate, and sorbitol; and
the ratio by weight of paclitaxel in the coating layer to the total weight of PEG (20) sorbitan monooleate and sorbitol in the coating layer is from about 0.1 to 5.
26. A method for treating a body passage, the method comprising:
removing plaque from a target site in the body passage by one of a debulking catheter, a laser atherectomy, a directing atherectomy, or a rotational atherectomy;
inserting a balloon catheter to the target site in the body passage, the balloon catheter comprising a balloon and a coating layer overlying external surfaces of the balloon, wherein:
the coating layer comprises a water-soluble first additive, a water-soluble second additive, and an initial drug load of a hydrophobic therapeutic agent;
the coating layer does not include an iodine covalent-bonded contrast agent, a dye, an oil, or a lipid;
the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, paclitaxel analogues, rapamycin, rapamycin analogues, and combinations thereof;
the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;
the water-soluble first additive is a surfactant selected from the group consisting of PEG sorbitan monolaurates, PEG sorbitan monooleates, and combinations thereof;
the water-soluble second additive is a chemical compound having at least four hydroxyl groups, the chemical compound being selected from the group consisting of sorbitol, sorbitan, xylitol, gluconolactone, and combinations thereof,
whereby the combination of the water-soluble first additive and the water-soluble second additive promotes rapid release of the hydrophobic therapeutic agent from the balloon at the target site during an inflation period;
inflating the balloon until the coating layer contacts walls of the body passage at the target site;
deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 10 minutes; and
withdrawing the balloon catheter from the body passage, the balloon having thereon a residual drug amount after the withdrawing.
27. The method of claim 26 , wherein:
the coating layer consists essentially of the therapeutic agent, the first additive, and the second additive;
the hydrophobic therapeutic agent is paclitaxel;
the water-soluble first additive is PEG (20) sorbitan monolaurate or PEG (20) sorbitan monooleate; and
the water-soluble second additive is sorbitol or gluconolactone.
28. The method of claim 27 , wherein:
the initial drug load is from 2 μg to 6 μg of the hydrophobic therapeutic agent per square millimeter of the balloon; and
the residual drug amount is 24.7% or less of the initial drug load.
29. The method of claim 26 , wherein the ratio by weight of the therapeutic agent in the coating layer to the total weight of the first and second additives in the coating layer is from about 0.5 to 3.